

August 26, 2019



## Anixa Biosciences to Present at Two Upcoming Investor Conferences

SAN JOSE, Calif., Aug. 26, 2019 /PRNewswire/ -- [Anixa Biosciences, Inc.](#) (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system to fight cancer, today announced its participation at two upcoming investor conferences in New York City.

Management will provide an overview of the company's business during live presentations and will be available to participate in one-on-one meetings with investors who are registered to attend the conferences.

Details of Anixa's presentations are as follows:

**Event:** Rodman & Renshaw's 21<sup>st</sup> Annual Global Investment Conference

**Date:** Monday, September 9, 2019

**Time:** 2:35 p.m. EDT

**Location:** Holmes I (4<sup>th</sup> Floor)  
Lotte New York Palace Hotel, New York, NY

**Event:** Janney Healthcare Conference

**Date:** Tuesday, September 10, 2019

**Time:** 11:50 a.m. EDT

**Location:** Bates Room  
The Union League Club, New York, NY

The Rodman & Renshaw conference presentation will be webcast live and remain available for 90 days following the presentation. To access the webcast, please visit the investors section of Anixa's website at <https://www.anixa.com>.

**About Anixa Biosciences, Inc.**

[Anixa](#) is a publicly-traded biotechnology company focused on harnessing the body's immune system in the fight against cancer. Anixa's therapeutics portfolio includes a cancer immunotherapy program, which uses chimeric endocrine receptor t-cell (CER-T) technology, a novel type of CAR-T, and a cancer vaccine technology focused specifically on triple negative breast cancer (TNBC), the most lethal form of the disease. Anixa's diagnostics portfolio includes the Cchek™ liquid biopsy technology, a series of inexpensive non-invasive blood tests for early detection of solid tumors based on the body's immune response to the presence of a malignancy. Anixa continually examines emerging technologies in complementary fields for further development and commercialization. Additional information is available at [www.anixa.com](http://www.anixa.com).

**Forward-Looking Statements:** Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

Anixa contact:  
Mike Catelani  
[mcatelani@anixa.com](mailto:mcatelani@anixa.com)  
408-708-9808

[Tiberend Strategic Advisors, Inc.](#)

Sharen Tilman (Investors)  
[stilman@tiberend.com](mailto:stilman@tiberend.com)  
646-604-5149

Johanna Bennett (Media)  
[jbennett@tiberend.com](mailto:jbennett@tiberend.com)  
212-375-2686

View original content to download multimedia <http://www.prnewswire.com/news-releases/anixa-biosciences-to-present-at-two-upcoming-investor-conferences-300906564.html>

SOURCE Anixa Biosciences, Inc.